Clinical trials: Microvascular Dysfunction
Hypertension
Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients
The purpose of this study is to determine if Nebivolol improves microvascular perfusion in skeletal muscle during exercise in hypertensive patients and whether this improvement is accompanied by reduction in vascular oxidative…
- Trial name
- NCT01501929
- Testing
- Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Coronary Microvascular Dysfunction
Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
This study is being done to evaluate the role of a novel implantable device, called The Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in symptomatic patients with coronary…
- Trial name
- Reducer (NCT04523168)
- Testing
- The Neovasc Reducer™ System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Amir Lerman
Microvascular Dysfunction
Cheese Consumption and Human Microvascular Function
Increased dairy intake is associated with improved measures of blood vessel health. Dairy cheese, however, is often high in sodium. Dietary sodium can impair blood vessel function.
- Trial name
- NCT03376555
- Testing
- Low sodium no cheese, Low sodium cheese, High sodium no cheese
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Lacy Alexander
Erectile Dysfunction
Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction
The purpose of this research study is to evaluate whether the combination of Shock Wave Therapy (SWT) with Platelet Rich Plasma (PRP) is synergistic and can reverse the pathology of microvascular Erectile Dysfunction (ED) and…
- Trial name
- COCKTAIL (NCT05048667)
- Testing
- Shock Wave therapy (SWT), Platelet Rich Plasma (PRP)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Miami
Metabolic Syndrome, Coronary Microvascular Dysfunction
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with…
- Trial name
- NCT05711719
- Testing
- Vericiguat
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins University
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
The aim of this study is to assess microvascular function as determined by a cardiovascular magnetic resonance measurement of whole-heart (global) perfusion reserve.
- Conditions
- Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
- Trial name
- NCT03249272
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Ischemic Heart Disease
EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
Some women have chest pain even without having a blockage in one of the major blood vessels that supplies blood to the heart. In many of these women the microscopic (small) blood vessels in the heart do not function normally.
- Trial name
- NCT00187889
- Testing
- Eplerenone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Florida
Coronary Microvascular Dysfunction
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease.
- Trial name
- NCT03508609
- Testing
- CLBS16
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Lisata Therapeutics, Inc.
Prediabetes, Obese
Inflammation Inhibition in Prediabetic Humans
Prediabetes, characterized by elevated fasting blood sugar or exaggerated blood sugar response to sugar ingestion, effects over 79 million adult Americans and is a precursor to the development of Type 2 diabetes.
- Trial name
- INCITE (NCT01977417)
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Gary L. Pierce
Atherosclerotic Vascular Disease, Type2 Diabetes
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Experimental models have linked lipid lowering therapies with systemic inflammation; however, relatively little is known about this network in clinical populations and specifically how it changes with PCSK9 inhibition.
- Conditions
- Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction
- Trial name
- NCT03829046
- Testing
- Evolocumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Robert Rosenson
Myocardial Reperfusion Injury
Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Percutaneous coronary intervention (PCI) for acute coronary syndromes frequently fails to restore myocardial perfusion despite establishing epicardial vessel patency.
- Trial name
- BQ-123 (NCT00586820)
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Microvascular Coronary Dysfunction (MCD)
Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
This research study is designed to test the use of ranolazine in patients with angina (chest discomfort due to reduced blood supply to the heart) due to microvascular coronary dysfunction (MCD; abnormalities in the small blood…
- Trial name
- RWISE (NCT01342029)
- Testing
- Ranolazine
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- Cedars-Sinai Medical Center
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease.
- Conditions
- Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
- Trial name
- FREEDOM (NCT04614467)
- Testing
- CLBS16
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Lisata Therapeutics, Inc.
Preeclampsia
Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
Women who develop preeclampsia during pregnancy are more likely to develop cardiovascular disease later in life, even if they are otherwise healthy.
- Trial name
- NCT03482440
- Testing
- Salsalate Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Psoriasis, Cardiovascular Disease
MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the population, is associated with increased cardiovascular (CV) risk.
- Trial name
- MINIMA (NCT04271540)
- Testing
- Tildrakizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Marcelo F. Di Carli, MD, FACC
Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with…
- Trial name
- LIBERTY-HCM (NCT02291237)
- Testing
- Eleclazine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences